Introduction
Hepatocellular carcinoma (HCC) is a life-threatening disease and, according to global cancer statistics from 2012, the third leading cause of cancer-related deaths in men and the sixth in women, worldwide [1] . At present, sorafenib is the only drug available prolonging the life of patients with HCC. However, the non-specific uptake of the drug into healthy tissues leads to a high toxicity and a variety of serious adverse reactions [2] .
Sorafenib is a multi-kinase inhibitor targeting various receptor tyrosine kinases and rapidly accelerated fibrosarcoma (RAF) kinases. Hence, it reduces tumour growth leading to significantly improved survival rates [1, 2] . However, a pronounced lipophilicity of the molecule is responsible for the poor bioavailability and distribution of the compound into healthy tissues [2, 3] . As a consequence, drug therapy is accompanied by serious side effects and a high dose is required.
Against this background, nanocarrier-based delivery of sorafenib has the potential to improve drug therapy significantly. Theranostic nanodelivery systems offer a versatile combination of therapeutic and diagnostic features and have been applied to this task earlier [3, 4] . A variety of contrast agents such as gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), shorten the longitudinal relaxation time, and were widely used for both vascular and tumor magnetic resonance imaging (MRI) [4, 5] . One major limitation of this technique lies in the short half-life of the contrast agent as well as the poor specificity for the target site.
In this context, Gd-DTPA-conjugated human serum albumin (HSA) nanoparticles improved the contrast of MRI compared to Gd-DTPA aqueous solution in vivo [3] [4] [5] . Unfortunately, even after conjugation of polyethylene glycol (PEG) to the particle surface, HSA nanoparticles exhibit only short circulation time [6] and the potential for scale-up of this technology is rather limited [7] .
On the contrary, block copolymers comprising polylactic-co-glycolic acid (PLGA) and PEG were processed to nanoparticles at medium-scale using microfluidic technology [8] and emulsion techniques [9] . Recently, formulations manufactured by BIND Therapeutics successfully passed phase 1 clinical trials [10] . A major shortcoming of nanocarrier delivery can be the limited drug load resulting in a high excipient concentrations and administration volume [11] . Previous investigations reported the loading of sorafenib into PLGA nanoparticles achieving a drug load of 1.4% [12] . An oil-in-water single emulsion-solvent evaporation method was used. Preparations made with a nanoprecipitation-dialysis technique using a block copolymer comprising dextran and PLGA resulted in a drug load of 5.3% [13] .
To attain synergistic effects of cytostatic agents, co-delivery of drug molecules has been approached. By employing a novel sequential freeze-thaw method followed by ethanol coacervation, a core-shell construct was manufactured [14] . After preparation of a polyvinyl alcohol (PVA)-doxorubicin nanocore, a thin shell of HSA comprises sorafenib as a second drug molecule. A drug load of 2.4 % was reached. Lipid-polymer hybrid nanoparticles were synthesized for the co-delivery of doxorubicin and sorafenib to enhance efficacy in HCC therapy [15] .
Other approaches focused on theranostic drug delivery systems containing gadolinium (Gd) and sorafenib. Theranostic liposomal carriers with a drug content of 4.3 % [m/m] were produced [16] . Another system used a multiblock polymer comprising (poly(lactic acid)- [12] .
In the present study, the impact of three different techniques for the nanoencapsulation of sorafenib into PLGA and polyethylene glycol-poly(D,L-lactide-co-glycolide) copolymer (PEG-PLGA) nanocarriers have been compared and the effect of the encapsulation method on drug load and other physicochemical properties has been studied. Among the methods evaluated, namely nanoprecipitation, single and double emulsion-solvent evaporation, the single emulsion-solvent evaporation was found to result in the optimal product parameters, thus, this process was optimized with regards to the intended target product profile. In vitro cytotoxicity and cellular uptake were investigated in HepG2 cells. Finally, the nanoparticles were modified on their surface using a Gd complex resulting in a theranostic nanocarrier system. For this purpose, the encapsulation of HSA into nanoparticles as well as the covalent modification of the surface using HSA or polyethylene imine were approached.
Results and discussion
In recent years, a variety of preparation methods have been evaluated for the synthesis of nanocarrier devices. The current approach resulted in advanced theranostic drug carriers and compared the impact of manufacturing technology and surface modification on the physicochemical properties and in vitro features. Initially, a particle size between 100 and 300 nm [17] , a zeta potential of more than -15 mV [18, 19] , a high drug load and particle yield were identified as key criteria for formulation development. Among other aspects, the encapsulation efficiency and particle size play an important role in nanocarrier delivery. (Figure 3 ), but exhibited a high PDI value (>0.27), poor encapsulation 9 efficiency (<20 %) and particle yield (20-40 %) . A lower density of the particle system due to the hydrophilic side chains of the polymer is the most likely explanation. Considering the difficulties in nanoparticle preparation when using the nanoprecipitation method, later efforts were focused on nanoparticle manufacture by single and double emulsion techniques. PVA turned out to be the optimal stabilizing agent resulting in monomodal size distribution of the nanospheres (Figure 4 ), an increased drug load (10 % (m/m)) and parameters within the specified range for each of the three polymers (Table 1 ). A concentration of 10 mg/ml of the polymer (in DCM), an initial drug concentration of 10 % (m/m) and a water-to-oil ratio of 4:1 resulted in the particle properties presented in Table 1 .
Further increase of the drug amount from 10 % to 20 % resulted in elevated PDI values (Table   10 2) denoting the presence of larger aggregates formed during the preparation process. For optimized condition with 10 mg/ml encapsulating polymer concentration and 10 % initial drug ratio, In summary, the top-down approach using the emulsion technique turned out to be more robust compared to the nanoprecipitation method. The nanoparticles were in the size range and exhibited optimal properties for further processing.
b. Modification of the particle matrix using HSA co-encapsulation or surface coating techniques
To covalently bind the Gd complex to the particle surface, amino groups were introduced into the polymeric matrix. In a first approach, HSA was co-encapsulated into the nanoparticles using the double emulsion-solvent evaporation method. The HSA incorporation resulted in smaller particle size than with single emulsion method, although there was no significant difference between the diameters of nanoparticles formed using PLGA and PEG-PLGA 
c. Surface modification with gadolinium
Gd-DTPA was conjugated to the amino groups of the HSA molecules after incorporation or covalent binding of the protein to PLGA and PEG-PLGA nanoparticles. As expected, the modification of nanocomposites with gadolinium was limited by the availability of functional groups on the particle surface. Nanoparticles modified with HSA on their surface were characterized by a poor binding (PLGA: 1.5 mg Gd/g nanoparticle, PEG-PLGA: 1.4 mg Gd/g nanoparticle). Nanoparticles comprising HSA as part of their matrix structure exhibited a higher binding (PLGA 2.3 mg Gd/g nanoparticle, PEG-PLGA 3.2 mg Gd/g nanoparticle).
Nevertheless, further increase of the Gd content was achieved using a method described earlier [20] with some modification (see in 2.9.). Binding PEI to the surface of nanoparticles a significant increase in the Gd content was achieved (PLGA: 15.7 mg Gd/g nanoparticle, PEG-PLGA: 10.7 mg Gd/g nanoparticle).
d. Evaluation of contrast signal using in vitro MRI
The MRI properties of theranostic nanocarriers were investigated in vitro. Magnevist® aqueous solutions containing different concentrations were used as a reference. There was a linear correlation ( Figure 5 ) between the MRI signal and the Gd content in a range between 0.02 and 0.3 mg Gd/ml (with MRI intensities of 470-670 for 0.02 mg Gd/ml, and 1520-1750 for 0.3 mg Gd/ml). For nanoparticles exhibiting the highest content of Gd the theoretical particle concentration (calculated from a maximum injectable particle concentration of 10 mg/ml and the obtained Gd loading) fell into this calibration range. The signal intensities measured for the T1-weighed MRI were in good accordance with the ICP results. Earlier studies reported 4.7-8.5 mg Gd/g nanoparticle concentration in HSA nanoparticles after covalent linking of DTPA to the protein nanoparticles obtained by desolvation, which was found to be considerably high for in vivo MRI studies [5] . 
e. Storage stability of theranostic nanocomposite formulations
For PLGA particles a concentration of 3 % (w/v) lyoprotector has been used earlier [21] . The sorafenib loaded nanoparticles with a drug load of approximately 10 % were freeze dried in 13 the presence of 3 % (w/v) trehalose or mannitol. Both PLGA-sorafenib and PEG-PLGAsorafenib nanospheres remained stable during the time of storage. An increase in the PDI values was observed for formulations freeze-dried with mannitol (Table 3) . On this background, trehalose at a concentration of 3 % was identified to be the optimal lyoprotector for the developed particle system (Figure 6 ). (Figure 7) . Surprisingly, the release of PEG-PLGA was substantially slower, reaching a plateau at 50.6 ± 9.2 %. A specific interaction with the hydrophilic side chain could be responsible for this behaviour. 
g. Cellular uptake and cytotoxicity
The internalization rates of sorafenib containing nanoparticles in HepG2 cells were determined by flow cytometry. As expected, drug-loaded nanoparticles prepared using the pegylated polymer were taken up by significantly fewer cells (9.6 ± 3.3 %) than Resomer ® RG 752H PLGA-sorafenib nanoparticles (25.7 ± 4.9 %).
The biocompatibility of nanomedicines is important for the development of successful delivery systems. To examine the cytotoxicity of the blank and drug carrier nanoparticles HepG2 cells were treated with various concentration of nanoparticles. The active agent solution in DMSO was also investigated and all of the results were related to the negative control, that is, to the non-treated cells. As shown in Figure 8 , cell viability remains around 90 15 % when exposed with 100 g/well of both blank nanoparticles (50000 cells/well). The nontoxic feature of PEG-PLGA nanoparticles has already been verified by others (e.g. [4] ).
sorafenib showed a concentration dependent cytotoxicity in the HCC cells. The same concentration of free sorafenib exerted higher cytotoxicity compared to the microencapsulated sorafenib ( Figure 11 ). Pure DMSO at equivalent volume of the free sorafenib solution in DMSO was also incubated with cells to evaluate its cytotoxicity effect that was found to be non-negligible. Accordingly, the cytotoxicity difference of free and entrapped sorafenib might have derived from the accompanying DMSO. Surprisingly, the highest sorafenib concentration changed the cell viability due to neither the free nor the encapsulated drug significantly. 
Conclusions
Theranostic nanocomposites comprising PLGA or PEG-PLGA were loaded with the anticancer agent sorafenib and modified on their surface with the contrast agent Gd-DTPA. These nanospheres exhibited superior properties compared to the particle systems described in the literature. Finally, the top-down manufacture combined with a modification of the particle surface using PEI and Gd-DTPA resulted in a strong MRI signal, optimal stability features and a sustained release profile. On this background further investigations will focus on the in vivo performance of these nanocarriers. 
Experimental

b. Cell culture experiments in HepG2 cells
The human hepatoma cell line HepG2 was grown in Dulbecco‫׳‬s modified Eagle‫׳‬s medium supplemented with 10 % fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin.
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The cells were cultured at 37 ºC in a humidified atmosphere containing 5 % CO2. The cells were trypsinized, resuspended and precultured before use.
c. Preparation of nanoparticles using nanoprecipitation
In 
d. Preparation of nanoparticles using the single emulsion technique
e. Preparation of nanoparticles using double emulsion-solvent evaporation technique
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The double emulsion-solvent evaporation technique was tested for the co-encapsulation of HSA into the sorafenib nanoparticles. The entrapped protein was further used for the covalent modification of the particle surface using the Gd complex (see section 2.9.). In principle, the inner water phase was formed by 2.5 mg HSA in a volume of 0.1 ml of MilliQ water. This solution was added to the organic phase composed of 15 mg of Resomer® RG 752H or
Resomer® RGP d5055 dissolved in 1.5 ml DCM combined with 1.5 mg of sorafenib dissolved in 0.15 ml acetone. The first emulsification was performed by sonication using a Sonoplus HD2070, MS73 probe (Bandelin, Berlin, Germany) at an amplitude 10 % for 30 s.
Afterwards, the water-in-oil emulsion was pipetted into 6.0 mL of an aqueous solution of PVA (1 % (w/v)). The water-in-oil-in-water emulsion was formed by a second sonication step at an amplitude 15 % for 45 s. The organic solvents were evaporated over a time period of 2 h under magnetic stirring at atmospheric pressure and room temperature. The nanoparticles were centrifuged at 20,000 rpm for 25 min (Eppendorf Centrifuge 5424 R), washed trice and redispersed in 0.5 ml of phosphate buffer (pH 8), and after gravimetric analysis, the suspensions were diluted to 20 mg/ml nanoparticle concentration.
f. Particle morphology and particle size analysis
The morphology of nanocapsules was investigated after centrifugation and redispersion in the described medium. The samples were examined using a FEI Talos F200XG2 high-resolution analytical scanning/transmission electron microscope (S/TEM) operated at 200 keV (SEM, Thermo Fischer Scientific, Waltham, MA).
Additionally, the particle size and size distribution were determined using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) equipped with a backscatter detector at an angle of 173°. The particles were characterized for the volume mean diameter and polydispersity index (PDI).
g. Storage stability of nanoparticle formulations
To improve the physical stability of the colloidal dispersion during the time of storage, the nanoparticles were freeze-dried, and their storage stability was investigated after 6 months of storage. A concentration of 3 % (w/v) of two lyoprotectors (trehalose dihydrate or mannitol) was evaluated. The solid concentration was adjusted to 7 mg/ml of nanoparticles and the samples were put into a Christ Epsilon 2-7 freeze dryer (Martin Christ GmbH, Osterode am
Harz, Germany). The lyophilisation was conducted in two drying steps.
Initially, the temperature was decreased to −60 °C for 1 h to freeze the samples. Afterwards 
h. Nanoparticle yield and encapsulation efficiency
The nanoparticle yield was determined by microgravimetry. The drug loading and encapsulation efficiency were investigated dissolving an amount of 10 mg nanoparticles in 1 ml of DMSO. The solution was diluted to be within the detectable linear calibration range (1-20 g/L). The absorbance of the solutions was measured spectrophotometrically (Hitachi U-3000, Tokyo Japan) at 285 nm.
i. Biorelevant in vitro drug release test using the centrifugation method
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The biorelevant in vitro drug release test was conducted using a centrifugation method. In brief, an amount of 1.5 mg of the sorafenib-loaded nanocomposites was re-suspended in 1 ml of human blood plasma containing 0.03 % sodium azide as a preservative. The nanoparticle formulations in release medium were filled into 2 mL tubes, and incubated at a temperature of 37 °C in an Thermomixer (Eppendorf, Hamburg, Germany) for 12 days at 700 rpm. At predetermined time points, samples with a total volume of 0.2 ml were collected. After each sampling time point the medium was replenished. The nanoparticles were separated from the plasma by centrifugation (Eppendorf Centrifuge 5424 R, 20 min at 20,000 rpm). The pellet was dissolved in 0.5 ml DMSO and the sorafenib concentration was determined spectrophotometrically as described above.
j. Surface modification using human serum albumin and polyethyleneimine
The nanoparticle dispersions prepared by single emulsion technique were centrifuged and redispersed in phosphate buffer (pH 8) resulting in a nanoparticle concentration of 20 mg/ml.
To increase the number of free amino groups on the particle surface, HSA or PEI were covalently bound to the nanoparticle surface. A 50-fold molar excess of EDC and the same excess of NHS, both calculated to the molar polymer concentration, were dissolved in 0.5 ml phosphate buffer (pH 8) and incubated for 60 min, centrifuged and washed three times, and redispersed in 1.5 ml phosphate buffer (pH 8).
The obtained carbodiimide-activated nanoparticle dispersion was given into 0.5 ml phosphate buffer (pH 8) solution containing equimolar amounts of HSA or PEI, and shaken overnight at 20°C in an Eppendorf Thermomixer (Hamburg, Germany) at 700 rpm. Afterwards, the nanoparticles were dialysed for 2 h against 400 ml of MilliQ water using a 100 kDa membrane to remove residues of the dissolved polymers HSA or PEI, respectively. The dialysis step was repeated with fresh MilliQ water.
k. Conjugation of nanoparticles using the Gd-DTPA complex
Gd complex was coupled to the HSA or PEI containing nanoparticles via the activation by the carbodiimide compound. In order to activate the carboxyl groups in the Gd complex a 10-fold molar excess of Gd-DTPA (related to the (PEG-)PLGA) was dissolved in 1 ml buffer (pH8) and combined with a 5-fold molar excess of EDC and a 5-fold molar excess of NHS related to the Gd-DTPA. The resulting solution was incubated for 50 min and added to the purified nanoparticle suspension overnight. Non-reacted Gd-DTPA, EDC and NHS were removed by dialysis using membrane 3.5 kDa against 500 ml MilliQ for 2 h, and after changing the dialysis medium with 500 ml fresh MilliQ, for another 2h. The dialysed nanoparticle suspension was centrifuged and redispersed in 1.5 ml phosphate buffer.
l. Quantification of human serum albumin using the mBCA method
The crosslinked or co-encapsulated HSA content of the nanocomposites was determined by the mBCA method after centrifuging 0.1 ml nanoparticle dispersion, and removing the supernatant, while the pellet was dissolved in 0.5 ml DMSO. This solution was diluted 10-fold with MilliQ water, and incubated for 1 h at 60 ºC with the same volume of freshly prepared mBCA reagents mixture. DMSO was added to the calibrating HSA solution with the same ratio. After cooling the coloured mixtures to room temperature for 20 min, their absorbance was evaluated by spectrophotometry at 562 nm (Hitachi U-3000, Tokyo, Japan).
m. Quantification of gadolinium using ICP-OES
The Gd concentration was measured using inductively coupled plasma optical emission spectroscopy using a Spectro Genesis ICP-OES (Germany) simultaneous spectrometer with axial plasma observation.
Multielemental standards (Merck, standard solutions for ICP) were used for calibration. The limits of detection of the element was calculated according to equation 2:
The purified nanoparticles were dissolved in 5 M hydrochloric acid and diluted to be in the desired calibration range. In vitro cytotoxicity caused in HepG2 cells was assayed using MTT reagent. Cells were seeded (50000 cells/well) in 96-well plates. After 24 h pre-incubation, the growth media were replaced with 100 μl of fresh DMEM containing 10 % FBS and PLGA-sorafenib or PEG-PLGA-sorafenib nanoparticles. Three different sorafenib concentration levels of the added nanoparticles were applied: 6.25 g/ml, 12.5 g/ml and 25 g/ml, while the control samples were also supplied by the same concentration of free sorafenib in DMSO solution. After 24 h incubation 10 l/well MTT solution (5 mg MTT/ml) was added followed by further incubation for 2 h. The supernatant was removed, and then 0. 
q. Statistics
All data are expressed as the mean value ± standard deviation (SD), which were calculated and plotted using Microsoft Excel (Microsoft, Redmond, WA) and SigmaPlot 11.0 (Systat Software GmbH, Erkrath, Germany), respectively. All nanoparticle formulations were produced as three batches (n=3).
